Conferences - Results from #660

Viewing 661-680 of 11696 articles

EAU 2024: Photodynamic Diagnosis (PDD) Directed Biopsies vs White Light Bladder Mapping in Patients with Positive Cytology and Negative Preoperative Workup: An International Multicenter Retrospective Study

EAU 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab Nab-Paclitaxel Followed by Postsurgical Adjuvant Nivolumab in Patients with Muscle-Invasive Bladder Cancer

European Association of Urology (EAU) 2024 Congress Features New Data on Modern Technology Use in Bladder Cancer Care

EAU 2024: Adjuvant Immunotherapy After pT3a F IV /N0 at Nephrectomy: Is That Real High-Risk for All? Yes

EAU 2024: PARP-Inhibitors Only for Patients with Alterations in DNA Repair Genes: The Guidelines' View

EAU 2024: PARP-Inhibitors Only for Patients with Alterations in DNA Repair Genes: Yes

EAU 2024: Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through 18F-DCFPyL-PSMA-PET/CT Scans in Pre-Treatment Prostate Cancer Patients

EAU 2024: State-of-the-Art Lecture: Advancements in Cutting-Edge SBRT Therapy for Oligometastatic Kidney Cancer

EAU 2024: A Prospective, Comparative, Within-Patient Controlled Multicenter Phase III Study Comparing Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern HD 4K Equipment

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + Risk Calculators + MRI (The EAU Screening Algorithm)

EAU 2024: Non-Thermal Atmospheric Plasma Ablation for Intermediate Risk Non-Muscle Invasive Bladder Cancer: A First in Human Trial

EAU 2024: Is There a Role for BCG in Very High-Risk Non-Muscle Invasive Bladder Carcinoma? Multicenter Analysis of Oncological Outcomes and Risk Dynamics

EAU 2024: Subsequent Therapies After Intravesical BCG in Patients with Bladder Cancer: Analysis of Real-World Treatment Patterns

EAU 2024: PSMA-PET Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: a Phase 2 Randomized Controlled Trial

EAU 2024: Intravesical Administration of Durvalumab to Patients with High Risk Non-Muscle Invasive Bladder Cancer Who Experience BCG Failure. Final Results from a Phase II Study by the Hellenic GU Cancer Group

EAU 2024: The International Bladder Cancer Group Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts the Need for Intervention for Patients on Active Surveillance

EAU 2024: Three-Year Oncological Outcomes of the Randomized Phase II Trial ARNEO: Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer

EAU 2024: PSICHE Trial: PSMA Guided Approach for Biochemical Relapse After Prostatectomy- a Prospective Trial

EAU 2024: Two-Year Quality of Life (QoL) Outcomes of the Randomized Phase II Trial ARNEO: Neoadjuvant Degarelix with or without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer

EAU 2024: Does Audit, Feedback and Education Improve Quality Indicator Achievement and Reduce Early Recurrence Rates in TURBT Surgery for NMIBC? Results from the RESECT Cluster Randomised Trial

29
30
31
32
33
34
35
36
37
38